Who We Are

K. John Morrow Jr., PhD President/CEO Newport Biotech

K. John Morrow, Jr.

K. John Morrow, Jr.

My training is in the field of genetics (PhD, University of Washington, Seattle).  I did post doctoral study at the Istituto di Geneticà, Universitá di Pavia, Italy, and the Institute for Cancer Research (now the Fox Chase Cancer Center, Philadelphia PA). I have extensive experience in the academic community, including faculty positions at the University of Kansas and the Texas Tech University Health Sciences Center. I have authored over 60 peer-reviewed publications reporting original research in genetics, immunology, developmental biology, evolution, cancer biology and animal science.

I have been the principal investigator or co-principal investigator on over $2.5M of federal and privately funded research grants, and I was the principal investigator on a small business innovative research grant (SBIR) from the National Institutes of Health to Meridian Biosciences, Inc.

In addition to my academic experience, I have been associated with Meridian Bioscience, Inc., an immunodiagnostics firm located in Cincinnati, for the last 20  years. I was first Principle Investigator on a research project supported by the company, and later as Director of Biological Sciences Research at their Cincinnati facility. In addition to my involvement as a research scientist at Meridian, I have consulted for numerous private companies.

I serve on the editorial boards of Biopharm International http://www.biopharminternational.com/biopharm.

In 2009 I was awarded a Science Journalism Laureate for excellence in scientific writing from Purdue University.

I speak and write the Italian Language and work as a part time interpreter for Affordable Language Services in Cincinnati.

In 2016 I joined Point A Consulting (Louisville KY; http://pointaconsulting.com/ABOUT-POINT-A-CONSULTING) as part of a team evaluating an expansion proposal developed by a Southeastern US research institute. The study was completed and the Point A consulting team is now advising its clients on the specifics of its recommendations.

In December of 2016 I completed with Dr. Cheng Liu editorial work on a coillection of essays entitled "Biosimilars of Monoclonal Antibodies". The volume, published by John Wiley, is now available.  

On a personal note, my wife and I share a third floor early 20th century penthouse in Newport, Kentucky with four cats who are responsible for deciding critical issues.

Representative List of Publications

These are some of my writings (2020 only), including books, peer-reviewed papers, editorial comment and articles in biotechnology trade papers. My Complete bibliography is available on request.


302. Morrow, K. J. 2020.Selexis Cell Line Development Strategies. https://www.genengnews.com/topics/bioprocessing/selexis-cell-line-development-strategies/.


303. Morrow, K. J. 2020. Building Therapeutic Proteins through Plant Glycosylation: A Sweet Solution.  https://www.genengnews.com/topics/bioprocessing/building-therapeutic-proteins-through-plant-glycosylation-a-sweet-solution/ 


304. Morrow, K. J. 2020. Applying the Bioprocessing 4.0 Paradigm to Antibody Glycosylation. https://www.genengnews.com/topics/drug-discovery/applying-the-bioprocessing-4-0-paradigm-to-antibody-glycosylation/


305. Morrow, K. J. 2020. https://www.genengnews.com/topics/drug-discovery/univercells-designs-novel-drug-manufacturing-technology/ 


306. Morrow, K. J. 2020. Response to a ‘Pains Driven’ Approach to Facilities of the Future. March 3. https://www.genengnews.com/topics/bioprocessing/response-to-a-pains-driven-approach-to-facilities-of-the-future/

307. Morrow, K. J. 2020. Eric Langer: Ruminating on Bioprocessing 4.0. https://www.genengnews.com/topics/bioprocessing/ruminating-on-bioprocessing-4-0/ 

308.  Morrow, K. J. 2020. Further Adapting New Bioprocess Technology in an Era of Change. Genetic Engineering and Biotechnology News. March 10. https://www.genengnews.com/topics/bioprocessing/further-adapting-new-bioprocess-technology-in-an-era-of-change/

309. Is BioProcessing 4.0 a Conceptual Leap or Incremental Advance? Genetic Engineering and Biotechnology News. March 17. https://www.genengnews.com/topics/bioprocessing/is-bioprocessing-4-0-a-conceptual-leap-or-incremental-advance/


310. Morrow, K. J. 2020. Artificial Intelligence and Outsourcing Impact Bioprocessing Operations. Genetic Engineering and Biotechnology News. March 14.https://www.genengnews.com/topics/bioprocessing/artificial-intelligence-and-outsourcing-impact-bioprocessing-operations/


 311. Morrow, K. J. 2020. Bioprocessing 4.0 Impacting New Drug Development. Genetic Engineering and Biotechnology News. March 31.https://www.genengnews.com/topics/bioprocessing/bioprocessing-4-0-impacting-new-drug-development/

312. Morrow, K. J. 2020. Going from Small to Big in Bioprocessing: Roadblocks and Their Resolution. Genetic Engineering and Biotechnology News. April 7.     https://www.genengnews.com/topics/bioprocessing/going-from-small-to-big-in-bioprocessing-roadblocks-and-their-resolution/.

313. Morrow, K. J. 2020. How Advanced ‘Bioprocessing 4.0’ Technologies Impact Biomanufacturing. April 14.https://www.genengnews.com/topics/bioprocessing/how-advanced-bioprocessing-4-0-technologies-impact-biomanufacturing/?utm_medium=newsletter&utm_source=Bioprocessing+4.0&utm_content=01&utm_campaign=Bioprocessing+4.0_20200416&oly_enc_id=2893B1360867G7G


Latest Book:

Cheng Liu (Editor), K. John Morrow, Jr. (Editor). Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development. ISBN: 978-1-118-66231-1. 704 pages. December 2016. John Wiley and Sons, New York.


85. Morrow K. J. Combination Antibody Therapy for Cancer Treatment. Insight Pharma Reports. January 2016. http://www.insightpharmareports.com/Combination-Antibody-Therapy-Report/.

86. Cheng Liu (Editor), K. John Morrow, Jr. (Editor). Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development. ISBN: 978-1-118-66231-1. 704 pages. December 2016. John Wiley and Sons, New York.

Chapters in Books

71.  Deng, J.  X. K., Raju, T. S., and Morrow, K. J. 2004. Achieving Appropriate Glycosylation During the Scale-up of Antibody Production. In: Antibodies: Volume II, Novel Technologies and Therapeutic Use (ed: S. Subramarium) Kluver/Academic/Plenum Press. pp 53-78.

72. Morrow, K. J., and Dorsett, P. 2004. New Frontiers in Bioprocessing. IN: “Advances in Large Scale Biopharmaceutical Manufacturing and Scale-up Production.” Volume I. ASM Press, Rockville, MD, pp1-28.

73. Morrow, K.J., R. Bawa, and C. Wei. 2007. Recent advances in basic and clinical nanomedicine. In:  Medical Clinics of North America: Nanomedicine 91(5):805-844, Elsevier Inc., Philadelphia, PA.

74. Morrow, K. J. 2007 Advances in antibody manufacturing using mammalian cells. IN: Annual Review of Biotechnology 9:95-113. Editor: M. Raafat El-Gewely. Elsevier BV.

75. Morrow, K. J. 2007 Frontiers in Bioprocessing: 2006. IN: Advances in Biopharmaceutical Manufacturing. Editor: Eric S. Langer. (in Press), ASM Press.

Book Reviews

85. Morrow, K. J. “Recombinant Antibodies” by Breitling and Dubel. Quarterly Review of Biology 76(4):487, 2001.

86. Morrow, K. J. “Inside the FDA” by Fran Hawthorne. Biopharm International. June 2005.